Giovanni Di Maira

Giovanni Di Maira

Auto-generated profile, based on publicly available information

Giovanni Di Maira

Dipartimento di Medicina Interna, Università degli Studi di Firenze, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
GMG Di Maira
G Di Maira
Mauro SalviMauro Salvi
Mauro Salvi
GAGiorgio Arrigoni
Giorgio Arrigoni
OMO Marin
O Marin
SSS Sarno
S Sarno
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
Treatment of Jurkat cells with specific inhibitors of protein kinase CK2 induces apoptosis. Here we provide evidence that the antiapoptotic effect of CK2 can be at least partially mediated by upregulation of the Akt/PKB pathway. Such a conclusion is based on the following observations: (1) inhibition of CK2 by cell treatment with two structurally unrelated CK2 inhibitors induces downregulation of Akt/PKB, as judged from decreased phosphorylation of its physiological targets, and immunoprecipitate kinase assay; (2) similar results are observed upon reduction of CK2 catalytic subunit by the RNA-interference technique; (3) Akt/PKB Ser129 is phosphorylated by CK2 in vitro and in vivo; (4) such a phosphorylation of activated Akt/PKB correlates with a further increase in catalytic activity. These data disclose an unanticipated mechanism by which constitutive phosphorylation by CK2 may be required for maximal activation of Akt/PKB.

15 October 2008 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
MPMario Pagano
Mario Pagano
JBJenny Bain
Jenny Bain
ZKZygmunt Kazimierczuk
Zygmunt Kazimierczuk
SSStefania Sarno
Stefania Sarno
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
LPLuigi Pinna
Luigi Pinna
CK2 (casein kinase 2) is a very pleiotropic serine/threonine protein kinase whose abnormally high constitutive activity has often been correlated to pathological conditions with special reference to neoplasia. The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers. In the present study we show, by using a panel of approx. 80 protein kinases, that DMAT and its parent compound TBI (or TBBz; 4,5,6,7-tetrabromo-1H-benzimidazole) are potent inhibitors of several other kinases, with special reference to PIM (provirus integration site for Moloney murine leukaemia virus)1, PIM2, PIM3, PKD1 (protein kinase D1), HIPK2 (homeodomain-interacting protein kinase 2) and DYRK1a (dual-specificity tyrosine-phosphorylated and -regulated kinase 1a). In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3. In an attempt to improve selectivity towards CK2 a library of 68 TBB/TBI-related compounds have been tested for their ability to discriminate between CK2, PIM1, HIPK2 and DYRK1a, ending up with seven compounds whose efficacy toward CK2 is markedly higher than that toward the second most inhibited kinase. Two of these, K64 (3,4,5,6,7-pentabromo-1H-indazole) and K66 (1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole), display an overall selectivity much higher than TBB and DMAT when tested on a panel of 80 kinases and display similar efficacy as inducers of apoptosis.

1 June 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
CRChiara Raggi
Chiara Raggi
MTMaria Letizia Taddei
Maria Letizia Taddei
ESElena Sacco
Elena Sacco
NNNadia Navari
Nadia Navari
MCMargherita Correnti
Margherita Correnti
FMFabio Marra
Fabio Marra

15 December 2006 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
MPMario Pagano
Mario Pagano
GPGiorgia Poletto
Giorgia Poletto
GMGiovanni Di Maira
Giovanni Di Maira
Giorgio CozzaGiorgio Cozza
Giorgio Cozza
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
LPLuigi Pinna
Luigi Pinna

15 July 2009 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
Giorgio CozzaGiorgio Cozza
Giorgio Cozza
MMMarco Mazzorana
Marco Mazzorana
EPElena Papinutto
Elena Papinutto
JBJenny Bain
Jenny Bain
MEMatthew Elliott
Matthew Elliott
LPLuigi Pinna
Luigi Pinna
Emodin (1,3,8-trihydroxy-6-methyl-anthraquinone) is a moderately potent and poorly selective inhibitor of protein kinase CK2, one of the most pleiotropic serine/threonine protein kinases, implicated in neoplasia and in other global diseases. By virtual screening of the MMS (Molecular Modeling Section) database, we have now identified quinalizarin (1,2,5,8-tetrahydroxyanthraquinone) as an inhibitor of CK2 that is more potent and selective than emodin. CK2 inhibition by quinalizarin is competitive with respect to ATP, with a Ki value of approx. 50 nM. Tested at 1 μM concentration on a panel of 75 protein kinases, quinalizarin drastically inhibits only CK2, with a promiscuity score (11.1), which is the lowest ever reported so far for a CK2 inhibitor. Especially remarkable is the ability of quinalizarin to discriminate between CK2 and a number of kinases, notably DYRK1a (dual-specificity tyrosine-phosphorylated and -regulated kinase), PIM (provirus integration site for Moloney murine leukaemia virus) 1, 2 and 3, HIPK2 (homeodomain-interacting protein kinase-2), MNK1 [MAPK (mitogen-activated protein kinase)-interacting kinase 1], ERK8 (extracellular-signal-regulated kinase 8) and PKD1 (protein kinase D 1), which conversely tend to be inhibited as drastically as CK2 by commercially available CK2 inhibitors. The determination of the crystal structure of a complex between quinalizarin and CK2α subunit highlights the relevance of polar interactions in stabilizing the binding, an unusual characteristic for a CK2 inhibitor, and disclose other structural features which may account for the narrow selectivity of this compound. Tested on Jurkat cells, quinalizarin proved able to inhibit endogenous CK2 and to induce apoptosis more efficiently than the commonly used CK2 inhibitors TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole).

1 September 2006 in Blood
Verified
Journal Article
Closed access
PDF file
FPFrancesco Piazza
Francesco Piazza
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
CGCarmela Gurrieri
Carmela Gurrieri
BMBarbara Montini
Barbara Montini
LBLuca Bonanni
Luca Bonanni
Gianpietro SemenzatoGianpietro Semenzato
Gianpietro Semenzato
Casein kinase 2 (CK2) is a ubiquitous cellular serine-threonine kinase that regulates relevant biologic processes, many of which are dysregulated in malignant plasma cells. Here we investigated its role in multiple myeloma (MM). Analysis of MM cell lines and highly purified malignant plasma cells in patients with MM revealed higher protein and CK2 activity levels than in controls (normal in vitro-generated polyclonal plasma cells and B lymphocytes). The inhibition of CK2 with specific synthetic compounds or by means of RNA interference caused a cytotoxic effect on MM plasma cells that could not be overcome by IL-6 or IGF-I and that was associated with the activation of extrinsic and intrinsic caspase cascades. CK2 blockage lowered the sensitivity threshold of MM plasma cells to the cytotoxic effect of melphalan. CK2 inhibition also resulted in impaired IL-6-dependent STAT3 activation and in decreased basal and TNF-α-dependent IκBα degradation and NF-κB-driven transcription. Our data show that CK2 was involved in the pathophysiology of MM, suggesting that it might play a crucial role in controlling survival and sensitivity to chemotherapeutics of malignant plasma cells.